|
Jun 29
|
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
|
|
Jun 26
|
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
|
|
Jun 25
|
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
|
|
Jun 24
|
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
|
|
May 9
|
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
|
|
Mar 28
|
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
|
|
Mar 18
|
Opko and Entera focus on oral care for obesity and metabolic disorders
|
|
Mar 17
|
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
|